AU2003277906B2 - Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7 - Google Patents
Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7 Download PDFInfo
- Publication number
- AU2003277906B2 AU2003277906B2 AU2003277906A AU2003277906A AU2003277906B2 AU 2003277906 B2 AU2003277906 B2 AU 2003277906B2 AU 2003277906 A AU2003277906 A AU 2003277906A AU 2003277906 A AU2003277906 A AU 2003277906A AU 2003277906 B2 AU2003277906 B2 AU 2003277906B2
- Authority
- AU
- Australia
- Prior art keywords
- phl
- polypeptide
- phi
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims description 19
- 230000007815 allergy Effects 0.000 title claims description 18
- 208000026935 allergic disease Diseases 0.000 title claims description 16
- 229960005486 vaccine Drugs 0.000 title abstract description 4
- 241000746983 Phleum pratense Species 0.000 title description 24
- 239000013574 grass pollen allergen Substances 0.000 title description 6
- 230000000774 hypoallergenic effect Effects 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 188
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 175
- 229920001184 polypeptide Polymers 0.000 claims abstract description 128
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 65
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 42
- 230000000172 allergic effect Effects 0.000 claims abstract description 41
- 239000013573 pollen allergen Substances 0.000 claims abstract description 29
- 239000013566 allergen Substances 0.000 claims abstract description 25
- 230000002829 reductive effect Effects 0.000 claims abstract description 22
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 12
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 12
- 239000002157 polynucleotide Substances 0.000 claims abstract description 12
- 239000013598 vector Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims abstract description 7
- 239000003085 diluting agent Substances 0.000 claims abstract description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 40
- 230000002009 allergenic effect Effects 0.000 claims description 20
- 229960001340 histamine Drugs 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 238000002255 vaccination Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 73
- 230000027455 binding Effects 0.000 abstract description 33
- 239000012634 fragment Substances 0.000 abstract description 30
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 24
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 abstract description 22
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 210000002966 serum Anatomy 0.000 abstract description 13
- 125000000539 amino acid group Chemical group 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- 238000006467 substitution reaction Methods 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 6
- 241000219495 Betulaceae Species 0.000 abstract description 5
- 238000002965 ELISA Methods 0.000 abstract description 5
- 239000000020 Nitrocellulose Substances 0.000 abstract description 5
- 238000012217 deletion Methods 0.000 abstract description 5
- 230000037430 deletion Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 229920001220 nitrocellulos Polymers 0.000 abstract description 5
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract description 4
- 101710176384 Peptide 1 Proteins 0.000 abstract description 4
- 238000007792 addition Methods 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 abstract description 4
- 230000005875 antibody response Effects 0.000 abstract description 4
- 238000003556 assay Methods 0.000 abstract description 3
- 238000010790 dilution Methods 0.000 abstract description 3
- 239000012895 dilution Substances 0.000 abstract description 3
- 241000283074 Equus asinus Species 0.000 abstract description 2
- 230000002163 immunogen Effects 0.000 abstract description 2
- 230000009257 reactivity Effects 0.000 abstract description 2
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 76
- 229940024606 amino acid Drugs 0.000 description 67
- 229940046528 grass pollen Drugs 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 230000035772 mutation Effects 0.000 description 17
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 12
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 229960004784 allergens Drugs 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 206010040914 Skin reaction Diseases 0.000 description 5
- 208000024780 Urticaria Diseases 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011533 pre-incubation Methods 0.000 description 5
- 231100000430 skin reaction Toxicity 0.000 description 5
- 230000035483 skin reaction Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000002072 anti-mutant effect Effects 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940030577 timothy grass pollen extract Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 102220472975 Cytochrome c oxidase subunit 6B1_E24S_mutation Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000209504 Poaceae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- -1 glycine or alanine) Chemical class 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000208199 Buxus sempervirens Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102220481919 Probable rRNA-processing protein EBP2_D17A_mutation Human genes 0.000 description 2
- 102220554974 Putative transcript Y 10 protein_D59A_mutation Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 201000004338 pollen allergy Diseases 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000122205 Chamaeleonidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 244000052363 Cynodon dactylon Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016675 EF-hand domains Human genes 0.000 description 1
- 108050006297 EF-hand domains Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102220499127 F-box only protein 32_D52A_mutation Human genes 0.000 description 1
- 102220500129 F-box only protein 32_E59A_mutation Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 102100026842 Serine-pyruvate aminotransferase Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lock And Its Accessories (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021837.6 | 2002-09-27 | ||
| EP02021837A EP1403280B1 (en) | 2002-09-27 | 2002-09-27 | Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7 |
| PCT/EP2003/010701 WO2004029083A1 (en) | 2002-09-27 | 2003-09-25 | Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p 7 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003277906A1 AU2003277906A1 (en) | 2004-04-19 |
| AU2003277906B2 true AU2003277906B2 (en) | 2008-04-03 |
Family
ID=31970337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003277906A Ceased AU2003277906B2 (en) | 2002-09-27 | 2003-09-25 | Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7425333B2 (enExample) |
| EP (1) | EP1403280B1 (enExample) |
| JP (1) | JP4446887B2 (enExample) |
| AT (1) | ATE303402T1 (enExample) |
| AU (1) | AU2003277906B2 (enExample) |
| CA (1) | CA2500234A1 (enExample) |
| DE (1) | DE60205907T2 (enExample) |
| DK (1) | DK1403280T3 (enExample) |
| ES (1) | ES2244708T3 (enExample) |
| PT (1) | PT1403280E (enExample) |
| WO (1) | WO2004029083A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT501101B1 (de) * | 2004-12-02 | 2008-01-15 | Biomay Ag | Protein-allergen-derivat |
| EP2000531A1 (en) * | 2007-06-06 | 2008-12-10 | Biomay AG | Antigen presenting cells |
| FI20085601A0 (fi) * | 2008-06-18 | 2008-06-18 | Valtion Teknillinen | Menetelmä uusien hypoallergeenien valmistamiseksi immuuniterapiaa varten |
| GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| WO2015077442A2 (en) * | 2013-11-20 | 2015-05-28 | La Jolla Institute For Allergy And Immunology | Grass pollen immunogens and methods and uses for immune response modulation |
| CA2931112A1 (en) * | 2013-11-20 | 2015-05-28 | La Jolla Institute For Allergy And Immunology | Pan pollen immunogens and methods and uses for immune response modulation |
| WO2015131053A1 (en) * | 2014-02-28 | 2015-09-03 | Alk-Abelló A/S | Polypeptides derived from phl p and methods and uses thereof for immune response modulation |
| AU2018286932A1 (en) | 2017-06-23 | 2020-01-16 | Mabylon Ag | Anti-allergen antibodies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999034826A1 (en) * | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002501748A (ja) * | 1998-01-31 | 2002-01-22 | ユニバーシティ オブ アーカンソー | アレルギー反応を減少させるための方法および試薬 |
-
2002
- 2002-09-27 PT PT02021837T patent/PT1403280E/pt unknown
- 2002-09-27 ES ES02021837T patent/ES2244708T3/es not_active Expired - Lifetime
- 2002-09-27 EP EP02021837A patent/EP1403280B1/en not_active Expired - Lifetime
- 2002-09-27 DE DE60205907T patent/DE60205907T2/de not_active Expired - Lifetime
- 2002-09-27 DK DK02021837T patent/DK1403280T3/da active
- 2002-09-27 AT AT02021837T patent/ATE303402T1/de not_active IP Right Cessation
-
2003
- 2003-09-25 US US10/529,441 patent/US7425333B2/en not_active Expired - Fee Related
- 2003-09-25 AU AU2003277906A patent/AU2003277906B2/en not_active Ceased
- 2003-09-25 WO PCT/EP2003/010701 patent/WO2004029083A1/en not_active Ceased
- 2003-09-25 CA CA002500234A patent/CA2500234A1/en not_active Abandoned
- 2003-09-25 JP JP2004539028A patent/JP4446887B2/ja not_active Expired - Fee Related
-
2008
- 2008-08-11 US US12/189,703 patent/US20090074801A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999034826A1 (en) * | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
Non-Patent Citations (1)
| Title |
|---|
| FASEB JOURNAL (1999) vol. 13, pages 843-856 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060216314A1 (en) | 2006-09-28 |
| DE60205907D1 (de) | 2005-10-06 |
| US7425333B2 (en) | 2008-09-16 |
| ES2244708T3 (es) | 2005-12-16 |
| EP1403280A1 (en) | 2004-03-31 |
| EP1403280B1 (en) | 2005-08-31 |
| AU2003277906A1 (en) | 2004-04-19 |
| JP2006515984A (ja) | 2006-06-15 |
| CA2500234A1 (en) | 2004-04-08 |
| US20090074801A1 (en) | 2009-03-19 |
| DE60205907T2 (de) | 2006-02-16 |
| JP4446887B2 (ja) | 2010-04-07 |
| DK1403280T3 (da) | 2005-11-07 |
| PT1403280E (pt) | 2005-11-30 |
| ATE303402T1 (de) | 2005-09-15 |
| WO2004029083A1 (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090074801A1 (en) | Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p 7 | |
| EP1440979B1 (en) | Process for the preparation of hypoallergenic mosaic proteins | |
| US20090017051A1 (en) | Allergy vaccines and their preparation | |
| Zhu et al. | T cell epitope mapping of ragweed pollen allergen Ambrosia artemisiifolia (Amb a 5) and Ambrosia trifida (Amb t 5) and the role of free sulfhydryl groups in T cell recognition. | |
| EP2723373B1 (en) | Contiguous overlapping peptides for treatment of ragweed pollen allergy | |
| US20090098167A1 (en) | PHL P 1 Allergen Derivative | |
| CA2475073C (en) | Hypoallergenic polypeptides based on fish parvalbumin | |
| CN103874509B (zh) | 来自苹果的主要变应原Mal d 1的低变应原性变体 | |
| EP2794644B1 (en) | Hypoallergenic variants of phl p 5, the major allergen from phleum pratense | |
| US20140121356A1 (en) | Hypoallergenic mutant polypeptides based on fish parvalbumin | |
| HK1045810C (en) | Allergy vaccines and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |